Tidal waves of knowledge gather like-minded experts in Taihu; united in heart, physicians overcome stubborn diseases. On November 9, 2025, the academic exchange meeting themed "Embracing Heritage, Guarding New Beginnings with Good Fortune," hosted by Sinopharm Central Health, was grandly held in Wuxi, Jiangsu Province. The conference specially invited top experts in the field of breast cancer from tertiary hospitals in Wuxi, Nanjing, Suzhou, and other cities to focus on the treatment of advanced breast cancer. They shared clinical insights, sparked innovative ideas, advanced cutting-edge concepts, and translated them into practical diagnostic and therapeutic outcomes, while reaffirming the central role of fulvestrant in treatment. Mr. Satheeshkumar, General Manager of Dr. Reddy's Laboratories Limited (hereinafter referred to as Dr. Reddy's) Greater China region, attended the event in person and, together with Sinopharm Central Health, shared global practical experiences in the standardization of generic drugs.
From top-tier global quality to universal affordability: the healthcare equity practice of generic drugs.
In recent years, the treatment of advanced breast cancer has entered a new era of precise stratification and combination therapy to enhance efficacy. Key advances are focused on four major directions: the deepening of targeted therapy, breakthroughs in immunotherapy, elucidation of resistance mechanisms, and implementation of whole-course management. Among all subtypes, HR+/HER2- accounts for the highest proportion (approximately 70%), and endocrine therapy remains the foundational treatment regimen for these patients. Fulvestrant, as a classic estrogen receptor downregulator, continues to hold a stable and central position in treatment by virtue of its unique mechanism of action and flexible advantages in combination therapy.
The conference officially opened with an address by Professor Wu Xiaohong from the Department of Medical Oncology at the Affiliated Hospital of Jiangnan University. Professor Wu highly recognized the therapeutic value of high-quality imported generic drugs for both clinical practice and patients. As a classic endocrine therapy drug, fulvestrant has also provided many patients with the benefit of longer survival.
Mr. Satheeshkumar, General Manager of Dr. Reddy's Greater China region, shared that Dr. Reddy's, with 40 years of deep expertise in the generic drug field, has firmly established itself among the global top 10 generic pharmaceutical companies. In China, the company has achieved multiple "first" breakthroughs: the first imported generic drug manufacturer to receive consistency evaluation approval, the first Indian pharmaceutical company to obtain approvals for orphan drugs and oncology drugs in China, and the first Indian company to win a bid in the national volume-based procurement. He emphasized that the partnership with Sinopharm Central Health is by no means simply about supplying drugs—the core mission is to deliver world-leading pharmaceutical technologies and rigorous quality standards, enabling Chinese patients to gain faster access to globally aligned, high-quality, affordable medicines—because health cannot wait.
Mr. Sun Chaoyang, Manager of Sinopharm Central Health, shared that Fulkeruide® (fulvestrant injection) has been launched in more than 20 countries and regions worldwide. Dr. Reddy's strictly controls quality, subjecting products from raw materials to finished goods to over 200 quality control tests and 400 man-hours of testing, and has obtained FDA certification.
Mr. Zhou Tengxiao, Manager of the Nanjing Office, introduced that Sinopharm Central Health, as a one-stop distribution service provider for global pharmaceutical products, upholds the mission of "Bringing global good medicines, serving a healthy China." The company covers 14 major therapeutic areas, collaborates with imported drug manufacturers to ensure supply, and leverages a full-industry-chain ecosystem to provide integrated services.
Academic Online: 2025 ESMO Guidelines Add Fulvestrant Triple Therapy as First-Line Standard for HR+/HER2- Advanced Breast Cancer
Professor Zhou Hao from the First Affiliated Hospital of Soochow University interpreted the 2025 ESMO guidelines, highlighting the upgraded precision positioning of fulvestrant in HR+/HER2- advanced breast cancer. The three key updates are: expansion of biomarker testing to include PIK3CA/AKT1 mutations and PTEN loss (Level IA); addition of a new fulvestrant-based triple combination therapy for first-line treatment of primary resistance with PIK3CA mutations (INAVO120 study: ORR 54%, PFS 15.0 months); and more precise stratified treatment after CDK4/6i progression (multi-pathway combination regimens). Professor Zhou concluded that fulvestrant has become a cornerstone of precision targeted therapy, establishing a full-cycle treatment pathway based on "testing first, stratified treatment," thereby promoting precise, chemotherapy-free management of the disease.
Professor Chao Lin from Wuxi No. 2 People's Hospital concluded in his keynote speech that fulvestrant, as a landmark SERD in HR+/HER2- advanced breast cancer, has reshaped the landscape of endocrine therapy and serves as the cornerstone of treatment in this field. The 2025 ESMO guidelines have upgraded it to the core of precision combination therapy, covering multiple treatment scenarios, making it the preferred option for chemotherapy-free precision management throughout the entire disease cycle.
Clinical Practice: Whole-Course Management of Advanced Breast Cancer – Classic Endocrine Therapy Benefits Reaffirmed
Professor Xiao Han from the Affiliated Hospital of Jiangnan University shared two clinical cases of HR+ advanced breast cancer:
Case 1 (HR+/HER2- with bone metastases and myelofibrosis): The patient received fulvestrant plus denosumab, achieving a first-line PFS of 15 months while avoiding bone marrow risks.
Case 2 (HR+/HER2+ with multiple lymph node metastases, premenopausal): The patient received fulvestrant plus goserelin, dual anti-HER2 therapy (± nab-paclitaxel), achieving PR and a first-line PFS exceeding 12 months.
Both cases confirm that fulvestrant, as a core endocrine therapy agent, can be flexibly combined with other treatments to effectively extend disease control duration.
Following the case presentations, Professor Sun Jin from Jiangning Hospital Affiliated to Nanjing Medical University concluded: Both cases confirm that in the treatment of HR+ advanced breast cancer, fulvestrant, as a core endocrine therapy agent, significantly prolongs first-line PFS when used in combination regimens. It is key to individualized combination adaptation and disease control before resistance develops.
Classic Endocrine Agents: Targeted Synergy Upgrades and the New Precision Medicine Ecosystem
This conference was held in the form of an offline roundtable meeting, chaired by Professor Chao Lin from Wuxi No. 2 People's Hospital and Professor Sun Jin from Jiangning Hospital Affiliated to Nanjing Medical University. Participating experts engaged in in-depth discussions on HR+/HER2- advanced breast cancer, focusing on the latest findings regarding combination regimens of fulvestrant with targeted therapies such as CDK4/6 inhibitors, as well as considerations related to efficacy, safety, treatment sequencing, and case-based medication strategies.
The precise exploration and evolution of treatment paradigms for HR+/HER2- advanced breast cancer are deeply intertwined. Following progression on CDK4/6 inhibitors, the value of fulvestrant-based combination strategies has become increasingly prominent: combined with the AKT inhibitor capivasertib for patients with AKT pathway alterations, median PFS reaches 7.2 months with a 44% reduction in the risk of disease progression; the triple combination of fulvestrant plus the PI3Kα inhibitor inavolisib and palbociclib enables patients with PIK3CA mutations to achieve a PFS exceeding 15 months, breaking through the "6-month ceiling." This academic exploration confirms that the field has entered a precision era driven by genetic testing to guide combination therapy, where treatment selection becomes a delicate balance among target, efficacy, and safety.
Clinical practice and academic research in endocrine therapy for advanced breast cancer are deeply integrated, and the application scenarios for fulvestrant as a core therapeutic agent continue to expand: for patients with specific underlying conditions, fulvestrant combined with denosumab stabilizes disease control while mitigating risks; for those with ESR1 mutations, adding elacestrant reduces tumor markers and overcomes resistance; for the HR+/HER2+ subtype, combining fulvestrant with anti-HER2 therapy and goserelin achieves partial remission in metastatic disease. This multi-scenario exploration reveals that the field has entered an era of "individualized combination therapy," where the application of fulvestrant represents a precise calculation balancing efficacy, safety, and the patient's underlying condition.
Rooted in tradition, driven by innovation, dedicated to patients, connected to the world.
At the conclusion of the conference, Professor Wu Xiaohong summarized that fulvestrant, as a core pillar of precision endocrine therapy for advanced breast cancer, has achieved enhanced value through combination strategies in scenarios such as overcoming resistance, safely controlling tumors in special populations, and salvaging ESR1 mutation cases. At the same time, Professor Wu and the attending experts also expressed the hope that Sinopharm Central Health and Dr. Reddy's will collaborate to rapidly develop an oral formulation of the drug, benefiting a broader range of patients.
Clinical urgency drives treatment needs, and that urgency serves as the engine for corporate development and innovation. Sustained innovation is the source of enduring vitality for classic medicines. Sinopharm Central Health will always uphold its mission of "Bringing global good medicines, serving a healthy China." In the future, through greater international exchange and deeper collaboration, the company will strive to give back to patients a healthy future full of promise and rewards.